![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
FJ Ehlert
Department of Pharmacology, College of Medicine, University of California, Irvine.
The ability of gallamine to modify muscarinic receptor binding properties and to antagonize muscarinic receptor-mediated inhibition of adenylate cyclase activity was investigated in the rat myocardium. Gallamine caused parallel shifts to the right in the dose-response curves for inhibition of adenylate cyclase activity by the highly efficacious muscarinic agonist oxotremorine-M and the partial agonist Bm 5 [N-methyl-N-(1-methyl-4-pyrrolidino)-2-butynyl acetamide]. The nature of this effect was inconsistent with competitive inhibition, but could be explained by allosteric antagonism. Similar dissociation constants of 0.52 and 0.83 microM were estimated for gallamine on the basis of its ability to antagonize responses to oxotremorine-M and Bm 5, respectively. The maximum shift in the dose-response curve of Bm 5 caused by gallamine was 90-fold, whereas that of oxotremorine-M was only 49-fold. When measured by inhibition of the binding of the specific muscarinic antagonist [3H]N-methylscopolamine, the dissociation constant of gallamine was estimated to be 1.1 microM. The present results illustrate good agreement between the ability of gallamine to modify muscarinic receptor binding properties and to antagonize muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat heart.
This article has been cited by other articles:
|
|
 |
|
  F. J. Ehlert and M. T. Griffin Two-State Models and the Analysis of the Allosteric Effect of Gallamine at the M2 Muscarinic Receptor J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 1039 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Ehlert Analysis of Allosterism in Functional Assays J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 740 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zahn, N. Eckstein, C. Trankle, W. Sadee, and K. Mohr Allosteric Modulation of Muscarinic Receptor Signaling: Alcuronium-Induced Conversion of Pilocarpine from an Agonist into an Antagonist J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 720 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. M. Birdsall, T. Farries, P. Gharagozloo, S. Kobayashi, S. Lazareno, and M. Sugimoto Subtype-Selective Positive Cooperative Interactions Between Brucine Analogs and Acetylcholine at Muscarinic Receptors: Functional Studies Mol. Pharmacol., April 1, 1999; 55(4): 778 - 786. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. P. Caulfield and N. J. M. Birdsall International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors Pharmacol. Rev., June 1, 1998; 50(2): 279 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lanzafame, A. Christopoulos, and F. Mitchelson Three Allosteric Modulators Act at a Common Site, Distinct from that of Competitive Antagonists, at Muscarinic Acetylcholine M2 Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 278 - 285. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
